NCT07678775进行中（未招募）3 期
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants With Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 107
- 试验地点
- 20
- 主要终点
- Frequency and severity of treatment-emergent adverse events to assess long-term safety of BBP-418.
研究概览
简要总结
This is an open-label extension (rollover) study designed to evaluate the long-term safety and efficacy of BBP-418 (ribitol) in participants with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) who have previously participated in Study MLB-01-005 (Fortify).
Participants will receive BBP-418 administered orally at protocol-defined doses and schedules. The study will assess long-term safety through monitoring of adverse events, clinical laboratory evaluations, and other safety assessments. Efficacy will be evaluated using functional measures and other clinical endpoints relevant to LGMD2I/R9.
Participants will be followed for up to 36 months, with a final safety follow-up assessment conducted approximately 30 days after the last dose of study drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Completed Study MLB-01-005 on study drug through the final clinic visit (Month 36 or another qualifying end-of-study visit as determined by the Sponsor).
- •The participant (or parent/guardian) who signs the ICF understands the study procedures and agrees to participate in the study by giving informed consent (or assent, if <18 years of age).
- •Is willing and able to complete all study procedures according to the Schedule of Assessments.
- •A WOCBP or a nonsterile male participant must be willing to use an acceptable method of contraception from the time of consent through 30 days after the last dose of study drug in this study.
排除标准
- •Has developed clinically significant concomitant disease that would, in the Investigator's opinion, be likely to unfavorably impact study participation, including:
- •Any significant concomitant medical condition, including psychiatric, cardiac, renal, pulmonary, hepatic, or endocrine disease other than that associated with LGMD2I/R9
- •Any other significant laboratory, vital sign, ECG abnormality, clinical history, or finding
- •Is pregnant (based on the Baseline / Day 1 pregnancy test result) and/or breastfeeding or planning to conceive children within the projected duration of the study through 30 days after the last dose of study drug in this study.
- •Has active suicidal ideation, defined as having a suicide ideation score of 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan) or 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS at Baseline / Day 1.
研究组 & 干预措施
BBP-418
Experimental
Drug: BBP-418. Single arm.
干预措施: BBP-418 (ribitol) (Drug)
结局指标
主要结局
Frequency and severity of treatment-emergent adverse events to assess long-term safety of BBP-418.
时间窗: 36 months
Change from baseline in North Star Assessment for LGMD2I/R9 to assess long-term efficacy of BBP-418.
时间窗: 36 months
次要结局
- Change from baseline FVC (percent predicted, performed in a sitting position) for LGMD2I/R9 to assess long-term efficacy of BBP-418.(36 months)
- Change from baseline in PUL 2.0 total score for LGMD2I/R9 to assess long-term efficacy of BBP-418.(36 months)
- Change from baseline in 100MTT (m/s) for LGMD2I/R9 to assess long-term efficacy of BBP-418.(36 months)
- Change from baseline in Serum CK for LGMD2I/R9 to assess long-term biomarker changes in participants.(36 months)
- Change from baseline in 10MWT (m/s) for LGMD2I/R9 to assess long-term efficacy of BBP-418.(36 months)
- Change from baseline in 10MWT (10-meter walk test) (m/s) for LGMD2I/R9 to assess long-term efficacy of BBP-418.(36 months)
- Change from baseline FVC (forced vital capacity) (percent predicted, performed in a sitting position) for LGMD2I/R9 to assess long-term efficacy of BBP-418.(36 months)
- Change from baseline in PUL 2.0 (performance of the upper limb) total score for LGMD2I/R9 to assess long-term efficacy of BBP-418.(36 months)
- Change from baseline in 100MTT (100-meter timed test) (m/s) for LGMD2I/R9 to assess long-term efficacy of BBP-418.(36 months)
- Change from baseline in Serum CK (creatine kinase) for LGMD2I/R9 to assess long-term biomarker changes in participants.(36 months)
研究者
研究点 (20)
Loading locations...
相似试验
尚未招募
3 期
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)CTRI/2024/12/078555F. Hoffmann-La Roche Ltd2,000
已完成
3 期
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease2024-511553-22-00Celgene International II SARL462
招募中
3 期
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients with Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease.2023-510057-41-00Lib Therapeutics LLC590
尚未招募
3 期
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07632898Inhibikase Therapeutics484
招募中
2 期
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma StudyAsthma (Diagnosis)NCT07677059Kymera Therapeutics, Inc.264